X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to advance a pipeline of orally delivered enzymes targeting malabsorption syndromes and nutrient metabolism disorders, including ANG003, a novel broad-spectrum orally delivered enzyme replacement therapy.
Lead Product(s): ANG003
Therapeutic Area: Genetic Disease Product Name: ANG003
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Atum Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration October 04, 2023
Details:
If the therapy is successful, people with CF would be able to decrease the number of enzyme pills they must take to digest food properly from a handful of pills to only one per meal.
Lead Product(s): Enzyme-based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: $15.5 million Upfront Cash: Undisclosed
Deal Type: Funding April 04, 2023
Details:
The new funding will be used to advance preclinical development and early stage clinical trials for Synspira’s non-porcine enzyme replacement therapy, SNSP003.
Lead Product(s): SNSP003
Therapeutic Area: Gastroenterology Product Name: SNSP003
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: CF Foundation
Deal Size: $22.5 Million Upfront Cash: $14.0 million
Deal Type: Funding October 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
